Clinical Trial Update: S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer [Phase 2]

View source ↗

Summary

This clinical trial update reports results from the Phase 2 S0618 E7389 study of eribulin mesylate in patients with metastatic or recurrent head and neck cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Halaven (eribulin mesylate) (eribulin mesylate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Head and Neck Cancer | Phase 2 | Status: COMPLETED | Results posted: 2012-08-29